Abstract：One case of multiple myeloma (MM) with central nervous system (CNS) infiltration in remission stage is reported. The patient is a middle-aged female, who is diagnosed with MM and received PCD regimen (Bortezomib + Cyclophosphamide + Dexamethasone) for four courses of chemotherapy, and achieved complete remission. Consolidate one course of treatment, plan to carry out hematopoietic stem cell transplantation, sudden neurological symptoms, improve MRI, flow cytometry and other examinations, clearly diagnose MM complicated with CNS infiltration, and actively give systemic chemotherapy + intrathecal injection and other treatment. After reaching complete remission again, the condition deteriorated rapidly, multiple intracranial metastases, family members gave up treatment, continued to take Ibutinib orally after discharge, and died three months later. Based on the review of relevant literature at home and abroad, this paper expounds the incidence, clinical characteristics, diagnosis, treatment, and prognosis of this disease in detail. It is found that CNS invasion of MM is rare and progresses rapidly. The review, summary, and analysis of the treatment process of this patient shows that ibutinib single drug is an alternative treatment for this kind of patients.
安万花 王万里 郭淑利 王松云 王慧睿. 多发性骨髓瘤缓解期并发中枢神经系统浸润1例报道[J]. 中国医药导报, 2022, 19(20): 185-188.
AN Wanhua WANG Wanli GUO Shuli WANG Songyun WANG Huirui. One case of multiple myeloma with central nervous system infiltration in remission stage. 中国医药导报, 2022, 19(20): 185-188.
[1] Ruiz-Heredia Y，Sanchez-Vega B，Barrio S，et al. Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma：a case report [J]. J Oncol Pharm Pract，2019，25（4）：998-1002.
[2] Miki Y，Kamata K，Akemoto Y，et al. Leptomeningeal and intraventricular myelomatosis manifesting an aggressive form of communicating hydrocephalus [J]. Neuropathology，2021，41（3）：243-249.
[3] Pak N，Shakki Katouli F，Radmard AR，et al. Multiple cranial nerve palsy concomitant with leptomeningeal involvement in multiple myeloma：a case report and review of literature [J]. Int J Hematol Oncol Stem Cell Res，2018， 12（1）：8-13.
[4] 李新，黄仲夏.多发性骨髓瘤伴髓外病变研究进展[J].肿瘤学杂志，2020，26（2）：86-91.
[5] 中国医师协会血液科医师分会，中华医学会血液学分会，中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南（2020年修订）[J].中华内科杂志，2020，59（5）：341-346.
[6] Jurczyszyn A，Grzasko N，Gozzetti A，et al. Central nervous system involvement by multiple myeloma：a multi-institutional retrospective study of 172 patients in daily clinical practice [J]. Am J Hematol，2016，91（6）：575-580.
[7] Chen Y，Qiu Y，Fu H，et al. IgD multiple myeloma with central nervous system involvement：a case report and literature review [J]. Mol Clin Oncol，2021，15（4）：198.
[8] Dias A，Higashi F，Peres A，et al. Multiple myeloma and central nervous system involvement：experience of a Brazilian center [J]. Rev Bras Hematol Hemoter，2018，40（1）：30-36.
[9] Nieuwenhuizen L，Biesma DH. Central nervous system myelomatosis：review of the literature [J]. Eur J Haematol，2008，80（1）：1-9.
[10] Marchesi F，Masi S，Summa V，et al. Flow cytometry characterization in central nervous system and pleural effusion multiple myeloma infiltration：an Italian national cancer institute experience [J]. Br J Haematol，2016，172（6）：980-982.
[11] Grossman S，Krabak M. Leptomeningeal carcinomatosis [J].Cancer Treat Rev，1999，25（2）：103-119.
[12] Al-Sobhi E，Osoba AO，Karar A，et al. Multiple myeloma of the central nervous system：a clinicopathological review [J]. East Mediterr Health J，2009，15（6）：1570-1579.
[13] Fassas AB，Ward S，Muwalla F，et al. Myeloma of the central nervous system：strong association with unfavorable chromosomal abnormalities and other high-risk disease features [J]. Leuk Lymphoma，2004，45（2）：291-300.
[14] Hotta M，Ito T，Konishi A，et al. Multiple myeloma with central nervous system relapse early after autologous stem cell transplantation：a case report and literature review [J]. Intern Med，2021，60（3）：463-468.
[15] 周宏伟，周晓燕，王志红，等.ABCD方案治疗复发/难治性多发性骨髓瘤的效果[J].中国医药导报，2018，15（23）：80-83.
[16] Nahi H，Svedmyr E，Lerner R. Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement [J]. Eur J Haematol，2014， 92（5）：454-455.
[17] Harrison SJ，Spencer A，Quach H. Myeloma of the central nervous system—an ongoing conundrum [J]. Leuk Lymphoma，2016，57（7）：1505-1506.
[18] Badros A，Singh Z，Dhakal B，et al. Marizomib for central nervous system-multiple myeloma [J]. Br J Haematol，2017，177（2）：221-225.
[19] Gozzetti A，Cerase A，Lotti F，et al. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents：a retrospective survey of 50 patients [J]. Cancer，2012，118（6）：1574-1584.
[20] Egan PA，Elder PT，Deighan WI，et al. Multiple myeloma with central nervous system relapse [J]. Haematologica，2020，105（7）：1780-1790.
[21] Benjamin R. Advances in off-the-shelf CAR T-cell therapy [J]. Clin Adv Hematol Oncol，2019，17（3）：155-157.
[22] Paludo J，Painuly U，Kumar S，et al. Myelomatous involvement of the central nervous system [J]. Clin Lymphoma Myeloma Leuk，2016，16（11）：644-654.
[23] 孔炫栋，韦超，赵明.多发性骨髓瘤医源性颅内种植转移一例并文献复习[J].中华神经外科杂志，2021，37（6）：629-631.
[24] Richardson PG，Bensinger WI，Huff CA，et al. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma：phase 2 trial results [J]. Br J Haematol，2018，180（6）：821-830.
[25] Hajek R，Pour L，Ozcan M，et al. A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma [J]. Eur J Haematol，2020，104（5）：435-442.
京公网安备 11010502046598号